Search Videos and More
News
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber
he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
News
The RAS Moment for Pancreatic Cancer Research
Dana-Farber investigators are at the forefront of a new era in RAS therapeutics for pancreatic cancer research
News
From Discovery to Patient Care: Vitamin D analog shuts down pancreatic cancer’s shield in clinical trial
Small clinical trial led by Dana-Farber Cancer Institute builds on Salk Institute’s foundational research on vitamin D receptor and tumor microenvironment
News
The Next Wave of Immune Cell Therapy
From CAR T to eTCR: New immune cell therapies push beyond blood cancers
News
Dana-Farber Launches Colorectal Cancer Screening Program in Central Asia
Dana-Farber Cancer Institute's Center for Global Health launched the first colorectal cancer screening program in Central Asia this week, partnering with Uzbekistan’s Ministry of Health and National Cancer Center to pilot a sustainable, early detection model that could be scaled across the region.
News
Global Rise in Many Early-Onset GI Cancers Detailed in Two Dana-Farber Reviews, With Colorectal Cancer Leading the Trend
Early-onset gastrointestinal (GI) cancers are rising at alarming rates worldwide and, in the U.S., are increasing faster than any other type of early-onset cancer, including breast cancer, according to two recent literature reviews from Dana-Farber Cancer Institute.
News
Dana-Farber Report Shows Alarming Rise in Many Gastrointestinal Cancers in Young People
Dana-Farber experts report rising rates of colorectal, pancreatic, esophageal, and other less common GI cancers in people under 50 and point to important next steps.
News
Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds
Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
News
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds
A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.
News
What is Immunopeptidomics?
A burgeoning type of “omics” called immunopeptidomics is providing researchers with a powerful approach to discovering new ways to train a person’s immune system to fight cancer.
News
New Insights into Immunotherapy Targets for Pancreatic Cancer
Cancer research often focuses on gene mutations in the parts of the human genome that produce cellular machinery called proteins. But the rest of the genome — sometimes called the “dark genome” — can also play a role.
News
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors